KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Adaptive Biotechnologies (ADPT) Shares Outstanding (2018 - 2025)

Adaptive Biotechnologies' Shares Outstanding history spans 8 years, with the latest figure at $153.8 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 4.06% to $153.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $153.8 million, a 4.06% increase, with the full-year FY2025 number at $153.8 million, up 4.06% from a year prior.
  • Shares Outstanding hit $153.8 million in Q4 2025 for Adaptive Biotechnologies, up from $152.6 million in the prior quarter.
  • Over the last five years, Shares Outstanding for ADPT hit a ceiling of $153.8 million in Q4 2025 and a floor of $139.9 million in Q1 2021.
  • Historically, Shares Outstanding has averaged $145.7 million across 5 years, with a median of $144.7 million in 2023.
  • Biggest five-year swings in Shares Outstanding: increased 10.47% in 2021 and later rose 1.21% in 2022.
  • Tracing ADPT's Shares Outstanding over 5 years: stood at $141.4 million in 2021, then grew by 1.21% to $143.1 million in 2022, then increased by 1.38% to $145.1 million in 2023, then rose by 1.86% to $147.8 million in 2024, then increased by 4.06% to $153.8 million in 2025.
  • Business Quant data shows Shares Outstanding for ADPT at $153.8 million in Q4 2025, $152.6 million in Q3 2025, and $152.2 million in Q2 2025.